Perspective Therapeutics (CATX) Stock Forecast & Price Target

Compare

1,549 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CATX Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Perspective

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CATX Stock 12 Month Forecast

Average Price Target

$11.92

▲(396.67% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $11.92 with a high forecast of $18.00 and a low forecast of $5.00. The average price target represents a 396.67% change from the last price of $2.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,3.9046153846153846,5.079230769230769,6.253846153846154,7.428461538461539,8.603076923076923,9.777692307692307,10.952307692307693,12.126923076923077,13.301538461538462,14.476153846153846,15.650769230769232,16.825384615384614,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,3.436923076923077,4.1438461538461535,4.850769230769231,5.5576923076923075,6.264615384615384,6.9715384615384615,7.678461538461539,8.385384615384615,9.092307692307692,9.79923076923077,10.506153846153845,11.213076923076922,{"y":11.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.73,2.9046153846153846,3.079230769230769,3.253846153846154,3.4284615384615384,3.603076923076923,3.7776923076923077,3.9523076923076923,4.126923076923077,4.3015384615384615,4.476153846153846,4.650769230769231,4.825384615384616,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$11.92

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jeff Jones

Oppenheimer

$13

Buy

441.67%

Upside

Reiterated

11/25/25

Oppenheimer Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Buy

441.67%

Upside

Reiterated

11/25/25

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

Gregory Renza

Truist Financial

$8→$12

Buy

400.00%

Upside

Initiated

11/24/25

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

David Dai

UBS

$18→$7

Buy

191.67%

Upside

Reiterated

11/21/25

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

Yuan Zhi

B. Riley Securities

$12→$11

Buy

358.33%

Upside

Reiterated

11/17/25

B. Riley Securities Sticks to Their Buy Rating for Perspective Therapeutics (CATX)Lowering CATX PT from $12 to $11.

Robert Burns

H.C. Wainwright

$10

Buy

316.67%

Upside

Reiterated

11/12/25

Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience

Oliver McCammon

LifeSci Capital

$13

Buy

441.67%

Upside

Reiterated

11/11/25

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

David Nierengarten

Wedbush

$11

Buy

358.33%

Upside

Reiterated

11/11/25

Wedbush Keeps Their Buy Rating on Perspective Therapeutics (CATX)

Justin Walsh

JonesTrading

$18

Buy

650.00%

Upside

Reiterated

11/11/25

Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition PotentialWe see the share price weakness as a buying opportunity given our confidence in the potential of the company's Pb-212-based clinical pipeline and technology platform, particulary in the context of a data rich 2026. We continue to believe that CATX is a prime acquisition target with multiple Big Pharma players advancing radiopharmaceutical pipelines. We reiterate our Buy rating and $18 price target.

Jeet Mukherjee

BTIG

$14

Buy

483.33%

Upside

Reiterated

11/11/25

BTIG Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

Leonid Timashev

RBC Capital

$16

Buy

566.67%

Upside

Reiterated

11/10/25

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

Alec Stranahan

Bank of America Securities

Hold

108.33%

Upside

Reiterated

10/22/25

Hold Rating for Perspective Therapeutics Amid Efficacy Concerns and Competitive Challenges

Louise Chen

Scotiabank

$15

Buy

525.00%

Upside

Reiterated

07/10/25

Perspective Therapeutics (CATX) Receives a Buy from Scotiabank

Kemp Dolliver

Brookline Capital Markets

$11

Buy

358.33%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher Liu

Lucid Capital

$15→$20

Buy

733.33%

Upside

Reiterated

01/27/25

Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Perspective Therapeutics Inc (NYSE: CATX) to $20.00 (from $15.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jeff Jones

Oppenheimer

$13

Buy

441.67%

Upside

Reiterated

11/25/25

Oppenheimer Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$13

Buy

441.67%

Upside

Reiterated

11/25/25

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

Gregory Renza

Truist Financial

$8→$12

Buy

400.00%

Upside

Initiated

11/24/25

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

David Dai

UBS

$18→$7

Buy

191.67%

Upside

Reiterated

11/21/25

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

Yuan Zhi

B. Riley Securities

$12→$11

Buy

358.33%

Upside

Reiterated

11/17/25

B. Riley Securities Sticks to Their Buy Rating for Perspective Therapeutics (CATX)Lowering CATX PT from $12 to $11.

Robert Burns

H.C. Wainwright

$10

Buy

316.67%

Upside

Reiterated

11/12/25

Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience

Oliver McCammon

LifeSci Capital

$13

Buy

441.67%

Upside

Reiterated

11/11/25

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

David Nierengarten

Wedbush

$11

Buy

358.33%

Upside

Reiterated

11/11/25

Wedbush Keeps Their Buy Rating on Perspective Therapeutics (CATX)

Justin Walsh

JonesTrading

$18

Buy

650.00%

Upside

Reiterated

11/11/25

Jeet Mukherjee

BTIG

$14

Buy

483.33%

Upside

Reiterated

11/11/25

BTIG Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

Leonid Timashev

RBC Capital

$16

Buy

566.67%

Upside

Reiterated

11/10/25

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

Alec Stranahan

Bank of America Securities

Hold

108.33%

Upside

Reiterated

10/22/25

Hold Rating for Perspective Therapeutics Amid Efficacy Concerns and Competitive Challenges

Louise Chen

Scotiabank

$15

Buy

525.00%

Upside

Reiterated

07/10/25

Perspective Therapeutics (CATX) Receives a Buy from Scotiabank

Kemp Dolliver

Brookline Capital Markets

$11

Buy

358.33%

Upside

Initiated

03/10/25

Perspective Therapeutics initiated with a Buy at BrooklinePerspective Therapeutics initiated with a Buy at Brookline

Christopher Liu

Lucid Capital

$15→$20

Buy

733.33%

Upside

Reiterated

01/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Perspective Therapeutics

1 Month

xxx

Success Rate

10/17 ratings generated profit

Average Return

+9.53%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.82% of your transactions generating a profit, with an average return of +9.53% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

+23.71%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +23.71% per trade.

1 Year

Jeff JonesOppenheimer

Success Rate

4/20 ratings generated profit

Average Return

-6.25%

reiterated a buy rating 12 days ago

Copying Jeff Jones's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -6.25% per trade.

2 Years

xxx

Success Rate

0/6 ratings generated profit

Average Return

-45.20%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -45.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CATX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CATX has received 26 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CATX average Analyst price target in the past 3 months is 11.92.

Each month's total comprises the sum of three months' worth of ratings.

CATX Financial Forecast

CATX Earnings Forecast

Next quarter’s earnings estimate for CATX is -$0.36 with a range of -$0.42 to -$0.24. The previous quarter’s EPS was -$0.35. CATX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.

CATX Sales Forecast

Next quarter’s sales forecast for CATX is $231.00K with a range of $0.00 to $350.00K. The previous quarter’s sales results were $209.00K. CATX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CATX has Performed in-line its overall industry.

CATX Stock Forecast FAQ

What is CATX’s average 12-month price target, according to analysts?

Based on analyst ratings, Perspective Therapeutics, Inc.’s 12-month average price target is 11.92.

What is CATX’s upside potential, based on the analysts’ average price target?

Perspective Therapeutics, Inc. has 396.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CATX a Buy, Sell or Hold?

Perspective Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Perspective Therapeutics, Inc.’s price target?

The average price target for Perspective Therapeutics, Inc. is 11.92. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $5.00. The average price target represents 396.67% Increase from the current price of $2.4.

What do analysts say about Perspective Therapeutics, Inc.?

Perspective Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CATX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Perspective Therapeutics (CATX) Stock Forecast & Price Target

CATX Analyst Ratings

CATX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Perspective Therapeutics

CATX Analyst Recommendation Trends

CATX Financial Forecast

CATX Earnings Forecast

CATX Sales Forecast

CATX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts